FORT WORTH, Texas, October 8, 2025 – Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will feature a range of innovations across its broad portfolio of products at the American Academy of Optometry Annual Meeting (#Academy25), October 8–11, 2025, in Boston, MA. Alcon will host an engaging on-site program and showcasing a range of innovative products and Alcon’s latest advancements in dry eye, contact lenses, digital health, and practice support.

“At #Academy25, we look forward to equipping Eye Care Professionals with new educational tools during several exciting sessions and insights—from new clinical data on our product innovations to hands-on learning opportunities,” said Carla Mack, Head, Global and U.S. Professional Education and Development. “Together, these resources are designed to help practices streamline care and strengthen patient relationships with improved outcomes.”

WaterInnovations™ Data Demonstrate Contact Lens Comfort, Extended Wear Performance; Debut of Head-to-Head Data for PRECISION7 1-Week Lenses vs. Biweekly⁶

Alcon’s industry-leading WaterInnovations^TM contact lens portfolio will be on display during the meeting with new data highlighting strong patient satisfaction in comfort even after 16 hours of lens wear.⁷ Most notably, this year’s program will feature comparative study results with PRECISION7^® versus biweekly replacement options.

Alcon also continues to make strides in its digital offerings for patients and providers with MARLO, Alcon’s digital product ordering platform. MARLO’s newest feature, Mirror Import, streamlines patient entry by automatically pulling select order data from electronic health records (EHR) and point of service (POS) systems—saving time and reducing manual-entry errors. This feature will be available for on-site demos.

Continuing Dry Eye Innovation at #Academy25 

Alcon’s latest innovations in dry eye treatment take center stage at #Academy25 with TRYPTYR^® (acoltremon ophthalmic solution) 0.003% pivotal Phase 3 trial results and clinical insights. Recently approved by the U.S. FDA as a first-in-class topical ocular neuromodulator designed to stimulate natural tear production and address the signs and symptoms of Dry Eye Disease (DED).¹⁰

In addition, SYSTANE^® PRO, a preservative-free, triple-action artificial tear providing up to 12 hours of dry eye symptom relief and significant improvement from baseline in dry eye symptoms.^11*

Delivering an Immersive and Compelling Experience to Attendees 

Alcon’s on-site presence will extend beyond product demonstrations with a multitude of opportunities for all conference attendees to hear from leading experts and learn how Alcon’s latest advancements can support clinical practices. Alcon will be sponsoring the National Optometric Association expert panel discussion, as well as the Ophthalmic World Leaders (OWL) Signature Event, "From Adversity to Innovation".

To learn more, please visit https://www.myalcon.com/professional/events/aao-optometry/. While on-site, visit Booth #916 at #Academy25 for important information on Alcon’s innovative products and clinical studies. For a full list of abstracts and presentations, visit AlconScience.com.  

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 24,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

*47% of patients experience meaningful symptom relief at 12 hours (N=153)

About TRYPTYR^® (acoltremon ophthalmic solution) 0.003% 

INDICATIONS AND USAGE
TRYPTYR^® (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.
Use with Contact Lenses: TRYPTYR should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of TRYPTYR.
Adverse Reactions
In clinical trials, the most common adverse reaction was instillation site pain (50%).

Please click here for the TRYPTYR Full Prescribing Information

References

1. Acoltremon 0.003% Leads to a Statistically Significant Increase in Tear Volume and Tear Total Lipid Concentration: Phase 3b Study Results
2. Acoltremon 0.003% Leads to Reductions in Both the Frequency and Severity of Dry Eye Symptoms Within 14 Days: Integrated Analysis of COMET Studies
3. Acoltremon 0.003% Consistently Reduces Multiple Dry Eye Symptoms Within 14 Days: Integrated Analysis of the COMET-1, COMET-2 and COMET-3 Studies
4. Improvement in Visual Tasking Activities and Workplace Productivity After 14 Days of Acoltremon 0.003% Treatment: Integrated Analysis of COMET Studies
5. Clinical Performance Comparison of a Novel Weekly Replacement and a Biweekly Replacement Silicone Hydrogel Soft Contact Lens
6. Alcon Data on File, 2025.
7. How does TOTAL30 sphere perform in those who previously dropped out of contact lenses due to comfort or dryness
8. The impact of astigmatic contact lens correction with Delefilcon A on functional vision and symptoms associated with prolonged digital device use
9. TRYPTYR^® U.S. FDA Prescribing Information. 2025.
10. Alcon Data on File, 2025.
     

Connect with us on Facebook and LinkedIn 

Investor Relations

Daniel Cravens, Allen Trang
+ 41 589 112 110 (Geneva)
+ 1 817 615 2789 (Fort Worth)
[email protected] 

Media Relations

Steven Smith
+ 41 589 112 111 (Geneva)
+ 1 817 551 8057 (Fort Worth)
[email protected]